| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| BR9507023A (en) | 1994-03-07 | 1997-09-23 | Inhale Therapeutic Syst | Processes for aerosolizing an insulin dose for respiratory insulin delivery and for preparing an insulin composition and insulin composition |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| US5955108A (en)* | 1994-12-16 | 1999-09-21 | Quadrant Healthcare (Uk) Limited | Cross-linked microparticles and their use as therapeutic vehicles |
| GB9606188D0 (en)* | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
| GB9606677D0 (en)* | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
| GB9607035D0 (en)* | 1996-04-03 | 1996-06-05 | Andaris Ltd | Spray-dried microparticles as therapeutic vehicles |
| GB9610341D0 (en)* | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
| AU702955B2 (en)* | 1996-05-17 | 1999-03-11 | Quadrant Healthcare (Uk) Limited | Microparticles and their use in wound therapy |
| US5855913A (en)* | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US5985309A (en)* | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en)* | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| GB9615435D0 (en) | 1996-07-23 | 1996-09-04 | Andaris Ltd | Spray-dried product and its therapeutic use |
| GB9621825D0 (en)* | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
| US5961459A (en)* | 1996-10-19 | 1999-10-05 | Andaris Limited | Use of hollow microcapsules in diagnosis and therapy |
| AU6014098A (en)* | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems | Aerosolized hydrophobic drug |
| CA2277801C (en)* | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP1498115A1 (en)* | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| SE9700133D0 (en)* | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| EE04628B1 (en)* | 1997-09-29 | 2006-06-15 | Inhale Therapeutic Systems, Inc. | Powder with Perforated Microstructures and Method for Preparing a Microparticle Composition and Powder with Perforated Microstructures |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| SE9704186D0 (en) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| GB9727102D0 (en)* | 1997-12-22 | 1998-02-25 | Andaris Ltd | Microparticles and their therapeutic use |
| AU2540299A (en)* | 1998-02-20 | 1999-09-06 | Quadrant Healthcare (Uk) Limited | Products comprising fibrinogen for use in therapy |
| EP1273290A1 (en)* | 1998-06-24 | 2003-01-08 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| EP1089712B1 (en)* | 1998-06-24 | 2003-05-02 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| ATE289825T1 (en)* | 1999-04-21 | 2005-03-15 | 1355540 Ontario Inc | METHACOLINE OR HISTAMINE FORMULATIONS FOR DETECTING ASTHMA |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| CA2395129C (en) | 1999-12-20 | 2008-12-16 | Nicholas J. Kerkhof | Process for producing nanometer particles by fluid bed spray-drying |
| US8771740B2 (en)* | 1999-12-20 | 2014-07-08 | Nicholas J. Kerkhof | Process for producing nanoparticles by spray drying |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| MXPA02001323A (en) | 2000-05-10 | 2004-07-16 | Alliance Pharma | Phospholipid-based powders for drug delivery. |
| WO2001093837A2 (en)* | 2000-06-08 | 2001-12-13 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
| US6896906B2 (en) | 2000-12-21 | 2005-05-24 | Nektar Therapeutics | Storage stable powder compositions of interleukin-4 receptor |
| JP2005504715A (en) | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ，インコーポレイテッド | Inhalable particles with sustained release characteristics |
| GB0111420D0 (en)* | 2001-05-10 | 2001-07-04 | Biovector Solutions Ltd | Soluble polymer systems for drug delivery |
| JP4837892B2 (en) | 2001-11-01 | 2011-12-14 | ネクター セラピューティクス | Method for producing powder batch |
| DK1455755T3 (en) | 2001-11-20 | 2013-07-15 | Civitas Therapeutics Inc | Improved particle composition for delivery in lung |
| ATE508735T1 (en) | 2001-12-19 | 2011-05-15 | Novartis Ag | PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES |
| US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
| EP2526996B1 (en) | 2002-12-20 | 2019-09-11 | Xeris Pharmaceuticals, Inc. | Formulation for intracutaneous injection |
| KR20120080243A (en)* | 2003-05-28 | 2012-07-16 | 노바르티스 아게 | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
| CA2532837A1 (en) | 2003-07-18 | 2005-04-21 | Baxter International, Inc. | Method for preparing small spherical particles by controlled phase separation |
| DE10339197A1 (en)* | 2003-08-22 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried amorphous powder with low residual moisture and good storage stability |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| WO2005112893A1 (en) | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Microspheres comprising protein and showing injectability at high concentrations of said agent |
| RU2300369C1 (en)* | 2005-12-27 | 2007-06-10 | Наталья Ивановна Ларионова | Method for preparing polyelectolyte microparticles containing incapsulated substance and sensitive to environment composition alteration |
| US9017697B2 (en) | 2006-10-12 | 2015-04-28 | The University Of Queensland | Compositions and methods for modulating immune responses |
| EP2050437A1 (en)* | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| UA90013C2 (en)* | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Pharmaceutical composition containing insulin and process for the preparation thereof |
| EP2349219A4 (en) | 2008-09-29 | 2013-05-01 | Univ Mercer | BIOACTIVE ENCAPSULATION MATERIAL OF NANOSPHERES AND PROCESS FOR PREPARING NANOSPHERES |
| US10004790B2 (en) | 2008-09-29 | 2018-06-26 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| US11524058B2 (en) | 2008-09-29 | 2022-12-13 | The Corporation Of Mercer University | Oral dissolving films containing microencapsulated vaccines and methods of making same |
| US10463608B2 (en) | 2008-09-29 | 2019-11-05 | The Corporation Of Mercer University | Microneedle-based transdermal delivery system and method of making same |
| US9827205B2 (en) | 2008-12-12 | 2017-11-28 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
| EP2216054A1 (en) | 2009-02-06 | 2010-08-11 | ProFibrix BV | Biodegradable extravascular support |
| GB0909136D0 (en) | 2009-05-28 | 2009-07-01 | Profibrix Bv | Dry powder composition |
| GB0909131D0 (en) | 2009-05-28 | 2009-07-01 | Quadrant Drug Delivery Ltd | Dry powder fibrin sealant |
| AU2010252929B2 (en)* | 2009-05-28 | 2015-08-27 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| US8846105B2 (en) | 2010-01-08 | 2014-09-30 | Profibrix, B.V. | Dry powder fibrin sealant |
| WO2012012460A1 (en) | 2010-07-19 | 2012-01-26 | Xeris Pharmaceuticals, Inc. | Stable glucagon formulations for the treatment of hypoglycemia |
| BR112013010926A2 (en) | 2010-11-01 | 2016-08-23 | Univ Technology Sidney | immunomodulatory agents and their uses |
| CN103442695B (en) | 2011-03-10 | 2016-05-04 | Xeris药物公司 | Stable Formulation of Peptide Drugs for Parenteral Injection |
| EP3225235B1 (en) | 2011-03-10 | 2020-12-16 | Xeris Pharmaceuticals, Inc. | Stable peptide formulations for parenteral injection |
| RU2013155713A (en) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | COMPOSITIONS FOR TREATMENT OF THE RAS |
| BR112014010275A2 (en) | 2011-10-31 | 2017-04-18 | Xeris Pharmaceuticals Inc | diabetes treatment formulations |
| KR20140147891A (en) | 2012-04-13 | 2014-12-30 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Aggregate particles |
| KR102139393B1 (en)* | 2012-06-26 | 2020-07-29 | 지이 헬스케어 에이에스 | Preparation of composition comprising gas microbubbles |
| US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
| KR20150139830A (en) | 2013-02-01 | 2015-12-14 | 글리아로직스 인코포레이티드 | Compositions and methods for the treatment of neurodegenerative and other diseases |
| US9956287B2 (en) | 2013-02-06 | 2018-05-01 | Perosphere Inc. | Stable glucagon formulations |
| US9018162B2 (en) | 2013-02-06 | 2015-04-28 | Xeris Pharmaceuticals, Inc. | Methods for rapidly treating severe hypoglycemia |
| CN113768881A (en) | 2013-10-08 | 2021-12-10 | 人工智能治疗公司 | Rapamycin for the treatment of lymphangioleiomyomatosis |
| MX394266B (en) | 2014-04-04 | 2025-03-24 | Ai Therapeutics Inc | AN INHALED RAPAMYCIN FORMULA FOR TREATING AGE-RELATED CONDITIONS. |
| EP3149049B1 (en) | 2014-05-27 | 2022-10-26 | The University Of Queensland | Il-22 for use in treating metabolic disorders |
| US11129940B2 (en) | 2014-08-06 | 2021-09-28 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
| CA2963085C (en) | 2014-10-07 | 2023-02-21 | Lam Therapeutics, Inc. | An inhalable rapamycin formulation for the treatment of pulmonary hypertension |
| WO2016196976A1 (en) | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| EP3307295A1 (en) | 2015-06-10 | 2018-04-18 | Xeris Pharmaceuticals, Inc. | Use of low dose glucagon |
| US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
| US11628208B2 (en) | 2015-10-05 | 2023-04-18 | The Corporation Of Mercer University | System and method for microneedle delivery of microencapsulated vaccine and bioactive proteins |
| WO2017062463A1 (en) | 2015-10-05 | 2017-04-13 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| US20180110760A1 (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases |
| KR102646865B1 (en) | 2017-06-02 | 2024-03-11 | 엑스에리스 파머수티클스, 인크. | Precipitation-resistant small molecule drug formulation |
| WO2021090214A2 (en)* | 2019-11-04 | 2021-05-14 | Alesco S.R.L. | Sucrosomial® berberine, its compositions and their use |